Pancreatic ductal adenocarcinoma (PDAC) is a very aggressive neoplasm; it is always fatal and is the fifth most common cause of death from cancer in the Western world. No efficient treatment is currently available, so it is essential to develop new therapeutics. In our team, we interest in the cellular and molecular mechanisms controlling pancreatic cancer initiation, progression and metastatic dissemination. We are particularly interested in deciphering the precise role of the Transforming Growth Factor Signaling Beta (TGFβ), whose signaling is impaired in virtually all cases of pancreatic cancers. To that end, we develop murine models of pancreatic cancer with genetic alterations targeting different branches of TGFβ signaling. Eventually, we take advantage of these models to test new therapeutical approaches.